Zydus Wellness Q1 FY27 sales jump 66.7% to ₹1,430 crore; profit slips 7%

Zydus Wellness reported Q1 FY27 consolidated EBITDA growth of 55.3% to ₹242 crore, while net profit fell to ₹119 crore. Its Sugar Free, Glucon-D, Everyuth and Nycil brands retained strong category market shares.

— Source publishedTue, 4 Aug, 2026, 13:47 IST·First seen Tue, 4 Aug, 2026, 13:49 IST·Source The Hindu BusinessLine

What happened

Zydus Wellness reported Q1 FY27 net profit of ₹119 crore, down 7% year-on-year, while sales rose 66.7% to ₹1,430 crore and EBITDA increased 55.3%. Core

Key facts

  • Consolidated net profit: ₹119 crore, down 7% YoY
  • Consolidated net sales: ₹1,430 crore, up 66.7% YoY from ₹858 crore
  • EBITDA: ₹242 crore, up 55.3% YoY
  • Sugar Free market share: 96.1%
  • Glucon-D market share: 59.1%
  • Everyuth scrubs market share: 49.4%
  • Everyuth peel-off market share: 75.5%
  • Everyuth facial cleansing market share: 8.2%, ranked fourth
  • Nycil market share: 32.9%

Why this matters

Strong category positions across health, nutrition and personal care make Zydus Wellness a credible platform for bolt-on brands or partnerships that deepen its wellness portfolio.

What to watch

  • Organic sales growth excluding any acquired or newly consolidated business.
  • EBITDA margin trend versus the 55.3% EBITDA-growth rate and prior-year margin base.
  • Recurring versus one-off reasons for the 7% net-profit decline.
  • Advertising and promotional spending as a percentage of sales.
  • Raw-material and packaging-cost movements, especially their impact on gross margin.
  • Distribution expansion, modern-trade and e-commerce contribution, and rural demand trends.
  • Market-share changes for Sugar Free, Glucon-D, Everyuth and Nycil.
  • Management commentary on integration synergies, debt/finance costs and capital allocation.
  • Clarify the drivers of the net-profit decline, including finance costs, depreciation/amortization, tax rate, exceptional items and any acquisition-related expenses.
  • Prioritize integration and distribution synergies to convert elevated sales scale into EBIT and net-profit growth.
  • Use selective price-pack architecture and premiumization in Sugar Free, Everyuth, Glucon-D and Nycil to protect gross margin without materially ceding share.
  • Maintain targeted brand investment in high-growth channels while reducing low-return trade promotions.
  • Focus investor communication on organic versus inorganic sales growth and the expected timeline for margin and EPS normalization.